Jump to content

New Schedule 4 Entry for Cannabidiol for Therapeutic Use


Recommended Posts

The TGA is proposing the rescheduling of Cannabinoids

 

https://www.tga.gov.au/book/interim-decisions-matters-referred-expert-advisory-committee-acms-out-session-november-2014

2. Scheduling proposals referred to the Out of Session November 2014 meeting of the Advisory Committee on Medicines Scheduling 2.1 Cannabidiol Scheduling proposal

To create a new Schedule 4 entry for cannabidiol for therapeutic use with consideration of an Appendix D listing.

The delegate referred the proposal to the Advisory Committee on Medicines Scheduling (ACMS) for advice.

Substance summary

Cannabidiol is a cannabinoid compound which occurs naturally in Cannabis sativa plants. Cannabidiol has the chemical formula C21H30O2 and its CAS number is 13956-29-1. The pharmacology of cannabidiol is complex and has been well characterised in in-vitro environments.

Some cannabinoid compounds work by binding to the CB1 and CB2 receptors in the brain. Cannabidiol does not activate CB1 and CB2 receptors directly however it has effects on many other 'signalling' systems and can be considered a 'multi-target' drug. Some of the effects of cannabidiol may be attributed to inhibition of the inactivation of endocannabinoids, such as anandamide. Other effects may be related to the chemical properties of the compound as opposed to pharmacodynamic effects. For example, it is thought that the presence of two hydroxyl groups enables cannabidiol to have an anti-oxidant action.

There is evidence that cannabidiol affects serotonin receptors (5HT1A), adenosine uptake, nuclear receptors of the peroxisome proliferator-activated receptors (PPAR) family and other pharmacological targets. Its pharmacological targets include receptors, ion channels, enzymes and cellular uptake processes.

There are reports that cannabidiol possesses antiproliferative, pro-apoptotic effects and inhibits cancer cell migration, adhesion and invasion. Evidence is also accumulating that there are positive effects of cannabidiol in the vasculature, where cannabidiol may induce vasorelaxation.

Information about the pharmacokinetics of the substance in humans is also accumulating.

continue reading:

https://www.tga.gov.au/book/interim-decisions-matters-referred-expert-advisory-committee-acms-out-session-november-2014

 

I think this may be eluding to drugs like Sativex ... haven't read it all yet though

Edited by Matanuska Thunder
  • Upvote 1
Link to comment
Share on other sites

Join the conversation

You can post now and register later. If you have an account, sign in now to post with your account.

Guest
Reply to this topic...

×   Pasted as rich text.   Paste as plain text instead

  Only 75 emoji are allowed.

×   Your link has been automatically embedded.   Display as a link instead

×   Your previous content has been restored.   Clear editor

×   You cannot paste images directly. Upload or insert images from URL.

×
×
  • Create New...

Important Information

By using the community in any way you agree to our Terms of Use and We have placed cookies on your device to help make this website better. You can adjust your cookie settings, otherwise we'll assume you're okay to continue.